Purpose: Current standard of care conventional imaging modalities (CIM) such as X-ray computed tomography (CT) and bone scan can be limited for detection of metastatic prostate cancer and therefore improved imaging methods are an unmet clinical need. We evaluated the utility of a novel second-generation low molecular weight radiofluorinated prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) radiotracer, [ 18 F]DCFPyL, in patients with metastatic prostate cancer.
Introduction
Prostate cancer is the most common malignancy diagnosed in men in the USA [1] . Currently, men with known or suspected metastatic prostate cancer are most commonly evaluated and followed using the conventional imaging modalities (CIM) of contrast-enhanced computed tomography (CECT) of the chest, abdomen, and pelvis and [ 99 Tc]methylene diphosphonate bone scan (BS). Though these modalities are able to detect a large number of metastatic prostate cancer sites, they still suffer from limitations including regions of degenerative bone change that can appear as sclerotic lesions on CECT and have corresponding uptake on BS; lytic or infiltrative bone metastases that generate scant surrounding bony reaction and have no appreciable sclerosis on CECT or uptake on BS; and small lymph nodes (less than 1 cm short axis) that are not able to be definitively characterized as disease involved on CECT.
Within the context of these limitations, it should be noted that clinically applied positron emission tomography (PET) such as 2-deoxy-2-[ 18 [2] . A great deal of effort has therefore been expended in the development of new PET functional imaging agents that might allow for improved sensitivity and specificity in the detection of metastatic prostate cancer. Among these are compounds that localize in areas of high fatty acid synthesis ( [3] [4] [5] [6] [7] [8] [9] [10] [11] . Examples of new PET agents also include those targeting gastrin-releasing peptide (GRP) [12, 13] , glutamine [14, 15] , and the prostate-specific membrane antigen (PSMA) [16] [17] [18] [19] [20] [21] [22] .
PSMA is an attractive target given that is expressed on the cell surface of the vast majority of prostate cancers [23, 24] . Levels of PSMA expression are correlated with tumor aggressiveness including metastatic potential [25] [26] [27] [28] [29] . Our group has previously published data on detecting primary and metastatic prostate cancer using a first-in-class radiofluorinated small molecule inhibitor of PSMA, N-[N-[(S) 
Materials and Methods

Patient Population and Selection
Approval of this prospective study was granted by our hospital's Institutional Review Board (IRB) and all patients were imaged under the auspices of a Food and Drug Administration exploratory investigation new drug application (eIND 108943), ClinicalTrials.-gov Identifier:NCT02151760. The patients included in this manuscript are the same cohort that were previously described in our group's prior first-in-man publication on the biodistribution and dosimetry of [ 18 F]DCFPyL [17] . Written, informed consent was obtained from all participants. Important inclusion criteria for this study included histologic confirmation of prostate cancer, radiologic evidence of new or progressive metastatic prostate cancer on another imaging modality (CECT, BS, magnetic resonance imaging (MRI), ultrasound, [
18 F]FDG PET/CT, or [ 18 F]NaF PET/CT), and a prostate-specific antigen (PSA) serum level of at least 1 ng/ml. Eight out of the nine imaged patients met all of the inclusion criteria, though a single patient with a PSA level of 0.1 ng/ml on androgen deprivation therapy (ADT) and with no evidence of disease on CECT, BS, or pelvic MRI but with high clinical suspicion for pelvic disease recurrence was imaged following an IRB-approved planned protocol deviation.
Important exclusion criteria for this study included low Karnovsky performance status (G60); prostate brachytherapy implants; treatment with an investigational drug, biologic, or device within 30 days prior to trial enrollment; administration of another radioisotope within five physical half-lives of trial enrollment; radiation or chemotherapy within 2 weeks prior to trial enrollment; or prior history of another malignancy other than skin basal cell carcinoma. Additionally, patients could not have serum creatinine or bilirubin 93 times the upper limit of normal or have liver transaminases 95 times the upper limit of normal.
Nine patients were prospectively enrolled between July and September 2014. Seven of those patients had complete CIM including CECT of the chest, abdomen, and pelvis and BS; one patient had CECT of the abdomen and pelvis and BS; and one patient had no recent CIM. Selected demographic and clinical information from the patients is included in Table 1 .
Radiochemistry
The [
18 F]DCFPyL precursor (S)-di-tert-butyl-1,2-(3-((S)-6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)-ureido)-pentanedioate formate salt was manufactured using current good manufacturing practices as has been previously reported [32] 
PET/CT Protocol
Though the effect of the fasting state on [ 18 F]DCFPyL uptake is unknown, per our typical clinical PET protocol we asked patients remain nil per os (except for water and some medications) for at least 6 h prior to radiotracer injection. In particular, given that folate is a low-affinity ligand for PSMA and with theoretical potential to decrease binding of [ [23, 33, 34] , patients were specifically instructed to avoid multivitamins and folate supplements on the day of the examination.
18 F]DCFPyL PET/CT acquisition was performed on a Discovery DRX PET/CT scanner (GE Healthcare, Waukesha, WI) operating in 3D emission mode with CT-derived attenuation correction. Initially, a whole body (WB, from the top of the skull through the mid-thighs) CT was obtained (120 kVp, 80 mA maximum (auto-adjusting)). Subsequently, a bolus injection of 9 mCi (331 MBq) or less of [
18 F]DCFPyL was administered through a peripheral IV catheter. A series of four sequential PET acquisitions were then obtained (labeled PET1 through PET4) beginning immediately after injection, followed by the patient voiding his bladder, followed by a second CT scan and additional PET acquisition (PET5). For PET1, imaging was performed for 1 min per bed position; for PET 2, 2 min per bed position; for PET3 and PET4, 4 min per bed position; and for PET5, 4 min per bed position. The PET4 acquisition began at approximately 60 min post-injection, depending on the patient height due to number of bed positions, and the PET5 acquisition always began at 120 min post-injection. The acquired PET images were reconstructed using a standard clinical ordered subset expectation maximization (OSEM) algorithm.
Image Analysis
Based on information in our group's prior first-in-man manuscript [17] , the PET4 and PET5 imaging time points demonstrated high tumor-to-background ratios and the lesion-by-lesion analysis was carried out based on those acquisitions. The PET1-PET3 acquisitions were not further analyzed. [ 18 F]DCFPyL PET/CT images were viewed on a Mirada Medical workstation (Mirada Medical, Oxford, UK). Measurements of background uptake were obtained as mean standardized uptake value (SUV mean ) from the ascending aorta (blood pool), liver, a non-disease-involved vertebral body, and the right gluteus musculature. Two experienced nuclear medicine readers (SPR and SYC) examined the PET images and provided a consensus read on the location of abnormal uptake suspicious or equivocal for sites of metastatic or primary prostate cancer (defined as visually conspicuous above nearby background uptake at a site outside of the normal biodistribution of the radiotracer). Suspected sites of metastases or tumor on DCFPyL PET were quantified using maximum SUV (SUV max ). Correlative BS images were also reviewed on the Mirada by two experienced readers (SPR and SYC), again with consensus reached as to any sites felt to be positive or equivocal for disease involvement. Correlative CECT images were reviewed by a single expert reviewer (KJM).
Statistical Analysis
Estimates of the proportion of agreement in lesion detection between [ 18 F]DCFPyL PET, CECT, BS, and combined CIM were arrived at through general estimating equation (GEE) intercept-only regression models and an exchangeable correlation structure. This methodology accounts for intra-patient correlation in the scenario of multiple lesions being present in a single patient. Estimated proportion of agreement was also determined between the modalities based on type of lesion (lymph node, bone, or prostate/prostate bed). Average within-patient differences in SUV parameters were modeled using the same GEE approach and results are reported with model-based p values. Analyses were completed with R version 3.1.2 [35] .
Results
An example maximum intensity projection (MIP) image from a patient with numerous [ Fig. 1 . Normal radiotracer uptake within the lacrimal and salivary glands, liver, kidneys, and urinary bladder is noted. Both the PET4 and PET5 time points were considered for a lesion-by-lesion analysis. Indeed, the vast majority of [
18 F]DCFPyL-avid lesions were visible at both time points. However, a total of eight sites of mild subtle focal bone uptake were identified only on the PET5 images, with an example shown in Fig. 2 . Furthermore, the overall maximum standardized uptake values (SUV max ) normalized to lean body mass for the tumors demonstrated a statistically significant increase between approximately 1 and 2 h post-injection on the PET4 and PET5 scans, respectively, in an aggregate of all sites of abnormal [ 18 F]DCFPyL uptake (p = 0.01), for lymph node uptake (p = 0.03) and for bone uptake (p = 0.01), and a trend towards increased uptake on PET5 for other sites (prostate, prostate bed, peri-prostatic tissue, and other soft tissue lesions) (Fig. 3) . In comparison, measures of background [ 18 F]DCFPyL uptake in the mediastinal blood pool, gluteus muscle, and vertebral bodies showed a statistically significant trend towards decreasing uptake between PET4 and PET5, with statistically increased mild uptake in the liver (Supplementary Fig. 2 ). Given these findings, all further analysis for metastatic detection on [ Pathologic proof of metastatic prostate cancer is only available from one lesion (a rectal wall metastasis in patient 3); therefore, these sites of increased radiotracer uptake will generally be referred to as sites of putative or presumptive metastatic disease.
Of the lesions on PET5, 170 were considered definite and 1 lesion was considered to be equivocal; this high degree of certainty in lesion detection by the reviewers is likely related to the generally high tumor-to-background uptake demonstrated by [ 18 F]DCFPyL-avid lesions. Excluding the patient for whom no comparison CIM was available, there were 138 definite [
18 F]DCFPyL positive lesions and 1 equivocal lesion. In comparison, for the same patient cohort, CECT identified 31 lesions (20 definite and 11 equivocal), BS identified 18 lesions (13 definite and 5 equivocal), and combined CIM identified 45 lesions (30 definite and 15 equivocal). Additional details of lesion detection by modality for the eight patients with comparison CIM are included in Table 2 .
[ 18 F]DCFPyL was able to detect sites of putative prostate cancer in bone, lymph nodes, and the prostate bed and surrounding tissues. One of the patients imaged in this study had never undergone prostatectomy, and an intensely [ 18 F]DCFPyL-avid lesion was also seen in his in situ prostate. In all, 78 lesions were detected in bone, 95 were detected in lymph nodes, and 11 were detected in the prostate, prostate bed, or peri-prostatic tissues.
Given the wide numerical range of lesions detected among these patients, a GEE regression analysis was performed in order to take into account intra-patient clustering effects as described in the materials and methods section [36] . Based on this analysis, it was estimated that a proportion of 0.54 (95 % CI 0.34-0.72) of the lesions that were negative or equivocal on CIM would be positive on [ 18 F]DCFPyL PET. In contradistinction, it was estimated that a proportion of only 0.03 (95 % CI 0.01-0.08) of lesions that were negative or equivocal on [ Table 3 . Lesions that were positive on CIM but negative or equivocal on [ 18 F]DCFPyL PET were two densely sclerotic lesions on CECT and a BS lesion; 10 additional bone lesions that were negative on [ 18 F]DCFPyL PET were equivocal on CECT and/or BS. Similar to our observations with our first-generation compound, we found that [ 18 F]DCFPyL is able to identify multiple different types of lesions that are not well evaluated with CIM. One of these lesion types is the infiltrative or lytic bone metastasis. Such metastatic foci are notable for a lack of surrounding bony reaction/sclerosis, and as such are visually difficult to detect on CECT and can be ostensibly invisible on BS. An example of such a lesion is shown in Fig. 4 , with no evidence of a significant abnormality on either CECT or planar BS, but with intense [
18 F]DCFPyL uptake.
Another group of lesions that is well evaluated by [ 18 F]DCFPyL is small lymph nodes. While the high spatial resolution afforded by CECT certainly allows for the sensitive identification of small lymph nodes, specificity for metastatic disease involvement can be limited and often relies on simple measures such as a size threshold (for example, the 1-cm short axis cutoff that is used in RECIST to determine if a lymph node is diseaseinvolved). We encountered a number of examples of lymph nodes measuring much less than 1 cm in short axis that were intensely [ We also note that intense [ 18 F]DCFPyL uptake was present in the pelvic/peri-prostatic tissues of several patients. This can be an intrinsically difficult region to assess with CECT due to the limited soft tissue contrast available with that modality. MRI can effectively evaluate the pelvis both pre-prostatectomy and post-prostatectomy, though in the only patient in our study with a comparison MRI, the MRI demonstrated no evidence of disease recurrence whereas the [ 18 F]DCFPyL PET showed elevated radiotracer uptake in the rectal/peri-rectal soft tissues (Fig. 6) . The patient underwent a rectal exam and was found to have a palpable nodule along the left anterior rectum; a subsequent biopsy proved the presence of PSMA-positive prostate cancer.
Discussion
PSMA-based PET/CT is a rapidly emerging and highly promising means of imaging metastatic prostate cancer [16] [17] [18] [19] [20] [21] [22] . Both our work with radiofluorinated low molecular weight compounds as well as work with other groups with Zirconium-89 and Gallium-68 PSMA agents has highlighted this potential. Though a great deal of work remains to fully validate PSMA as a new clinical standard for the imaging of prostate cancer, the growing body of data suggesting superiority to CIM is promising. Indeed, in this study, we encountered a number of lesions, including the abovenoted non-sclerotic bone foci and small lymph nodes, for which PSMA-based PET/CT with [ Supplementary Fig. 3a is a MIP from a patient imaged with [
18 F]DCFBC and can be compared to Supplementary Fig. 3b which is representative of a patient imaged with [
18 F]DCFPyL. It is worth noting that a small number of lesions become visible between the PET4 and PET5 acquisitions. This concords with the observations that tumoral uptake, as measured by SUV max , and tumor-to-background ratios increased between PET4 and PET5 ( Fig. 3 and Supplementary Fig. 2 ). All eight of the sites of putative disease that became apparent on PET5 alone were bone lesions with relatively subtle uptake. An example is shown in Fig. 2 . It is likely that most patients with known metastatic prostate cancer being followed for disease progression or response to therapy would be well evaluated at 1 h post-injection (approximately the time of PET4), a time frame that would very conveniently fit into the work flow at most PET sites given the common practice of imaging FDG at that same time point. However, for selected patients, such as those with a low PSA in the context of a new biochemical recurrence, more delayed imaging at 2 h post-injection (i.e., the PET5 time point) may more definitively evaluate their disease status. Further evaluation of [
18 F]DCFPyL in such patient populations will help to determine the highest yielding and most convenient imaging protocol.
Emerging Gallium-68 PSMA PET agents have also been reported to have greatly improved detection of metastatic lesions in patients with biochemical recurrence after prostatectomy compared to conventional imaging [37] [40] . It will need to be determined in futures studies if there is a clinically significant difference between either Fluorine-18 or Gallium-68 PSMA agents for detection of metastatic prostate cancer, with the advantage of Gallium-68 including easier radiochemistry and generator produced Gallium-68 without requirement for an onsite cyclotron and potential integration to theranostic applications. The advantages to F-18 PSMA agents include ease of distribution utilizing pre-existing networks for FDG and improved spatial resolution and theoretically more accurate quantitation inherent in the shorter positron range and higher positron yield of F-18 versus Ga-68 [41] . 
Conclusion
PSMA-based PET/CT with the second-generation radiotracer [ 18 F]DCFPyL was able to identify a large number of putative sites of metastatic prostate cancer that were occult or indeterminate with conventional imaging. PET imaging at 2-h post-injection may improve tumor lesion detection compared to earlier time-point imaging but requires further verification. If these results are validated in larger prospective trials, [ 18 F]DCFPyL PET/CT may ultimately prove a more reliable means of identifying and following metastatic prostate cancer than currently available imaging methods.
